Fintel reports that on January 10, 2025, BMO Capital upgraded their outlook for Precision BioSciences (NasdaqCM:DTIL) from Market Perform to Outperform. Analyst Price Forecast Suggests 661.60% Upside ...

BMO Capital Markets upgraded shares of Precision BioSciences (NASDAQ:DTIL – Free Report) from a market perform rating to an outperform rating in a report released on Friday, Marketbeat Ratings reports ...

Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, is proud to announce ...

Precision BioSciences gains momentum as iECURE reports positive ECUR-506 data, and analysts forecast significant HBV program-driven stock growth.

Dario Scimeca, General Counsel and Secretary of Precision BioSciences Inc . (NASDAQ:DTIL), a biotechnology company with a market capitalization of $38 million and currently trading at $4.97, executed ...

Precision BioSciences Inc (DTIL) stock saw a modest uptick, ending the day at $5.7 which represents a slight increase of $1.20 or 26.67% from the prior close of $4.5. The stock opened at $6.8 and ...

JonesTrading analyst Soumit Roy maintained a Buy rating on Precision BioSciences (DTIL – Research Report) today and set a price target of ...

CARMEL, Ind., Jan. 23, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the ...

DURHAM, N.C., January 09, 2025--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing ...

H.C. Wainwright analyst Patrick Trucchio has reiterated their bullish stance on DTIL stock, giving a Buy rating today.Stay Ahead of the ...

(RTTNews) - Precision BioSciences, Inc. (DTIL), a clinical-stage gene editing company, on Thursday, announced positive clinical efficacy data from its partner iECURE in the Phase 1/2 OTC-HOPE ...